| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KRT6B |
| Uniprot No | P04259 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-564aa |
| 氨基酸序列 | ASTSTTIRS HSSSRRGFSA NSARLPGVSR SGFSSISVSR SRGSGGLGGA CGGAGFGSRS LYGLGGSKRI SIGGGSCAIS GGYGSRAGGS YGFGGAGSGF GFGGGAGIGF GLGGGAGLAG GFGGPGFPVC PPGGIQEVTV NQSLLTPLNL QIDPAIQRVR AEEREQIKTL NNKFASFIDK VRFLEQQNKV LDTKWTLLQE QGTKTVRQNL EPLFEQYINN LRRQLDNIVG ERGRLDSELR NMQDLVEDLK NKYEDEINKR TAAENEFVTL KKDVDAAYMN KVELQAKADT LTDEINFLRA LYDAELSQMQ THISDTSVVL SMDNNRNLDL DSIIAEVKAQ YEEIAQRSRA EAESWYQTKY EELQITAGRH GDDLRNTKQE IAEINRMIQR LRSEIDHVKK QCANLQAAIA DAEQRGEMAL KDAKNKLEGL EDALQKAKQD LARLLKEYQE LMNVKLALDV EIATYRKLLE GEECRLNGEG VGQVNISVVQ STVSSGYGGA SGVGSGLGLG GGSSYSYGSG LGVGGGFSSS SGRATGGGLS SVGGGSSTIK YTTTSSSSRK SYKH |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KRT6B重组蛋白的虚构参考文献示例(实际文献请通过学术数据库检索)：
1. **《Functional characterization of recombinant human KRT6B in epidermal differentiation》**
- 作者：Smith A, et al.
- 摘要：本研究成功在大肠杆菌中表达并纯化了重组KRT6B蛋白，通过体外实验证实其参与调控角质形成细胞的迁移和分化，为研究KRT6B在皮肤病中的作用提供了工具。
2. **《KRT6B mutations alter filament assembly: Insights from recombinant protein modeling》**
- 作者：Chen L, et al.
- 摘要：利用重组KRT6B蛋白及其突变体进行体外聚合实验，发现特定突变导致角蛋白纤维结构异常，解释了其在先天性厚甲症中的致病机制。
3. **《Recombinant KRT6B interacts with desmoplakin in vitro》**
- 作者：Wang X, et al.
- 摘要：通过pull-down实验发现重组KRT6B蛋白与桥粒蛋白desmoplakin存在直接结合，提示其在细胞间粘附中的潜在功能。
4. **《High-throughput screening of KRT6B-targeted compounds using recombinant protein-based assays》**
- 作者：Kim J, et al.
- 摘要：开发基于重组KRT6B蛋白的药物筛选平台，鉴定出多个小分子可调控KRT6B的稳定性，为靶向治疗提供候选分子。
**建议**：可通过PubMed或Google Scholar检索真实文献，关键词为“KRT6B recombinant protein”或“KRT6B expression and purification”。
**Background of KRT6B Recombinant Protein**
KRT6B (Keratin 6B) is a member of the keratin family, which constitutes intermediate filament proteins critical for maintaining structural integrity in epithelial cells. Expressed primarily in stratified epithelia, KRT6B plays a key role in forming cytoskeletal networks that provide mechanical resilience and regulate cell signaling. It is often co-expressed with other type II keratins (e.g., KRT5) and type I keratins (e.g., KRT14) to form heterodimers essential for epithelial tissue function.
Recombinant KRT6B protein is engineered through molecular cloning, typically using expression systems like *E. coli* or mammalian cell lines, to produce purified, functional protein for research. This recombinant form retains critical structural domains, including the conserved central α-helical rod domain and variable head/tail regions, enabling studies on keratin assembly, interactions, and disease-related mechanisms.
KRT6B is clinically significant due to its association with genetic disorders. Mutations in *KRT6B* are linked to pachyonychia congenita (PC), a rare autosomal-dominant skin disorder characterized by nail dystrophy, painful palmoplantar keratoderma, and oral lesions. Recombinant KRT6B facilitates *in vitro* modeling of PC, aiding investigations into mutation-induced filament instability and cellular stress responses. Additionally, KRT6B overexpression is observed in squamous cell carcinomas, suggesting its potential role in tumor progression.
Researchers utilize recombinant KRT6B to develop antibodies, screen therapeutic compounds, and study epithelial barrier dysfunctions. Its availability in a purified, bioactive form accelerates mechanistic studies, bridging genetic insights to therapeutic strategies for keratin-related diseases.
×
